Analytical Data
-
Gene name
BDNF
- Application
-
Alternative Names
BdnfBrain-derived neurotrophic factor; BDNF) [Cleaved into: BDNF precursor form; ProBDNF)]
-
Species
Human
-
Source
E. coli
-
Tag
N- Myc
-
Purity
Greater than 90% as determined by SDS-PAGE.
-
Uniprot
P23560
-
Expression Region
19-247aa
-
Protein Length
Partial
-
Molecular Weight
25.8 kDa
-
Endotoxin
< 1.0 EU per μg protein as determined by the LAL method.
-
Form
Freeze-dried powder
-
Buffer formulation
PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300.
-
Reconstitution
Reconstitute in ddH2O to a concentration of 0.1-0.5 mg/mL. Do not vortex.
- Customization
-
Stability Test
The thermal stability is described by the loss rate. The loss rate was determined by accelerated thermal degradation test, that is, incubate the protein at 37℃ for 48h, and no obvious degradation and precipitation were observed. The loss rate isless than 8% within the expiration date under appropriate storage condition.
-
Storage & Shelf Life
Samples are stable for up to twelve months from date of receipt at -20℃ to -80℃. Store it under sterile conditions at -20℃ to -80℃. It is recommended that the protein be aliquoted for optimal storage. Avoid repeated freeze-thaw cycles.
-
Shipping
In general, recombinant proteins are supplied as lyophilized powder and shipped at ambient temperature. For bulk packages, the proteins are provided as frozen liquid and shipped with blue ice, unless otherwise requested by the customer.
Quality inspection process
Related Products
Protein Description
Brain-derived neurotrophic factor (BDNF) is a crucial neurotrophic protein that plays a significant role in neuronal survival, differentiation, and synaptic plasticity, making it essential for cognitive function and mental health. Abnormalities in BDNF signaling are implicated in various neurological and psychiatric disorders, including depression, schizophrenia, and neurodegenerative diseases like Alzheimer's. Given its vital functions, BDNF has become a focal point in biomedical research, particularly regarding its therapeutic potential. The exploration of BDNF recombinant proteins has gained momentum as researchers aim to harness its beneficial effects in treating conditions characterized by neurotrophic deficits. The ability to produce recombinant BDNF allows for the study of its properties in vitro and in vivo, providing valuable insights into its mechanisms of action and potential applications in therapy. Various expression systems, such as bacteria, yeast, and mammalian cells, have been employed to produce functional BDNF. However, challenges remain in ensuring proper folding, post-translational modifications, and bioactivity of the recombinant protein. Understanding these aspects can help optimize BDNF-based therapies and develop novel strategies for promoting brain health and recovery in individuals suffering from neurological impairments. As the field advances, ongoing research into the production, delivery, and efficacy of BDNF recombinant proteins holds promise for unlocking new avenues for treating a range of neurodevelopmental and neurodegenerative disorders.
